https://socictopen.socict.org/files/original/72df527d4f001b66b0edfac9249ae59e.pdf afd00e19a664e32dfbb2cd1ec0c2a6d9 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. Creator An entity primarily responsible for making the resource Seyede Atefe Hosseini, Fatemeh Zahedipour, Hamed Mirzaei, Reza Kazemi Oskuee Description An account of the resource Since September 2020, the world has had more than 28 million cases of coronavirus disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 outbreak. A pressing need is evident for the development of a potent vaccine to control the SARS-CoV-2. Institutions and companies in many countries have announced their vaccine research programs and progress against the COVID-19. While most vaccines go through the designation and preparation stages, some of them are under evaluation for efficacy among animal models and clinical trials, and three approved vaccine candidates have been introduced for limited exploitation in Russia and China. An effective vaccine must induce a protective response of both cell-mediated and humoral immunity and should meet the safety and efficacy criteria. Although the emergence of new technologies has accelerated the development of vaccines, there are several challenges on the way, such as limited knowledge about the pathophysiology of the virus, inducing humoral or cellular immunity, immune enhancement with animal coronavirus vaccines, and lack of an appropriate animal model. In this review, we firstly discuss the immune responses against SARS-CoV-2 disease, subsequently, give an overview of several vaccine platforms for SARS-CoV-2 under clinical trials and challenges in vaccine development against this virus. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource vaccine, SARS-CoV-2, Therapy Identifier An unambiguous reference to the resource within a given context 10.1016/j.intimp.2021.107622 Source A related resource from which the described resource is derived International immunopharmacology